Innovation in Microbiome Research to Prevent C. diff, Antimicrobial Resistance and Improve GI Health
https://www.youtube.com/watch?v=fPZQa5jbXtk
Upcoming Events
Digestive Disease Week (DDW 2017)
May 6–May 9, 2017
Chicago, IL
May 7, 2017
Poster Su2012: Poster Su2012: Increased pulmonary CO2 Excretion in Patients with Small Intestinal Bacterial Overgrowth (SIBO): Possible Implications for COPD
Session Number 7245 from 12:00 p.m. – 2:00 p.m. CDT
Venue: McCormick Place, South Hall
Poster Su1562: Initial paradoxical peaks on breath testing (first sample high) do not affect the diagnostic utility of the spot-methane breath test
Session Number 7130 from 12:00 p.m. – 2:00 p.m. CDT
Venue: McCormick Place, South Hall
Lecture 332g: An Orally Delivered Beta-Lactamase Protects the Gut Microbiome from Antibiotic-Mediated Damage and Mitigates the Propagation of Antibiotic-Resistance Genes in a Porcine Dysbiosis Model.
Session Number 3505 from 2:15 p.m. – 2:30 p.m. CDT
Venue: McCormick Place, room S503
May 9, 2017
Lecture 874j: SYN-004 (ribaxamase), an Oral ß-Lactamase, Prevented Clostridium difficile Infection and Protected Patients from Colonization by Antimicrobial Resistant Pathogens by Preserving Gut Microbiome Diversity in a Phase 2b Clinical Trial
Session Number 5235 from 10:30 a.m. – 10:45 a.m. CDT
Venue: McCormick Place, room S103
Association for Professionals in Infection Control and Epidemiology (APIC 2017)
June 14–June 17, 2017
Portland, OR
Microbiome Drug Development Summit
June 28–June 29, 2017
Boston, MA
=================================================
Yesterdays conference call
https://www.webcaster4.com/Webcast/Page/1096/20882
Slide show...
https://www.sec.gov/Archives/edgar/data/89415...ex99-1.htm
Possibly there's already a transcript out.
Snagging a partnership is still possible but I didn't get the vibe that he has one in the net yet. In fact he mentioned Japan and other potential sources including a couple large investors (private placement?) and of course would not rule out a raise.
Burn rate will drop dramatically in the mean time since they're done with the ribaxamase trial. So I'm thinking a little patience through the conferences in June to see what happens.
The CDC likes what they see. So do I. Just a matter of patience and seeing how the stock holds up in the short term.
$SYN
https://www.youtube.com/watch?v=fPZQa5jbXtk
Upcoming Events
Digestive Disease Week (DDW 2017)
May 6–May 9, 2017
Chicago, IL
May 7, 2017
Poster Su2012: Poster Su2012: Increased pulmonary CO2 Excretion in Patients with Small Intestinal Bacterial Overgrowth (SIBO): Possible Implications for COPD
Session Number 7245 from 12:00 p.m. – 2:00 p.m. CDT
Venue: McCormick Place, South Hall
Poster Su1562: Initial paradoxical peaks on breath testing (first sample high) do not affect the diagnostic utility of the spot-methane breath test
Session Number 7130 from 12:00 p.m. – 2:00 p.m. CDT
Venue: McCormick Place, South Hall
Lecture 332g: An Orally Delivered Beta-Lactamase Protects the Gut Microbiome from Antibiotic-Mediated Damage and Mitigates the Propagation of Antibiotic-Resistance Genes in a Porcine Dysbiosis Model.
Session Number 3505 from 2:15 p.m. – 2:30 p.m. CDT
Venue: McCormick Place, room S503
May 9, 2017
Lecture 874j: SYN-004 (ribaxamase), an Oral ß-Lactamase, Prevented Clostridium difficile Infection and Protected Patients from Colonization by Antimicrobial Resistant Pathogens by Preserving Gut Microbiome Diversity in a Phase 2b Clinical Trial
Session Number 5235 from 10:30 a.m. – 10:45 a.m. CDT
Venue: McCormick Place, room S103
Association for Professionals in Infection Control and Epidemiology (APIC 2017)
June 14–June 17, 2017
Portland, OR
Microbiome Drug Development Summit
June 28–June 29, 2017
Boston, MA
=================================================
Yesterdays conference call
https://www.webcaster4.com/Webcast/Page/1096/20882
Slide show...
https://www.sec.gov/Archives/edgar/data/89415...ex99-1.htm
Possibly there's already a transcript out.
Snagging a partnership is still possible but I didn't get the vibe that he has one in the net yet. In fact he mentioned Japan and other potential sources including a couple large investors (private placement?) and of course would not rule out a raise.
Burn rate will drop dramatically in the mean time since they're done with the ribaxamase trial. So I'm thinking a little patience through the conferences in June to see what happens.
The CDC likes what they see. So do I. Just a matter of patience and seeing how the stock holds up in the short term.
$SYN
